Share Prices & Company Research

Stockbroking

Hikma Pharmaceuticals

Current Price 888.60p Bid 891.80p Ask 892.20p Change -0.65%
Last Updated: 24/02/2018 16:03. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

Financial Highlights Year Ended 31/12/2016

Turnover
£1,950.00m
Operating Profit
£302.00m
Dividend Yield
2.23
Dividend Per Share
33.00
Dividend Cover
2.02
P/E Ratio
14.29

Key Personnel

Said Darwazah
Executive Chairman
Mazen Samih Darwazah
Executive Vice Chairman
Mary Regina Henderson
Non-Executive Director
John J Castellani
Non-Executive Director
Dr Jochen Gann
Non-Executive Director
Ali Al-Husry
Non-Executive Director
Michael Richard Dwyer Ashton
Non-Executive Director
Dr Ronald Lane Goode
Non-Executive Director
Dr Pamela Josephine Kirby
Non-Executive Director
Robert Mark Pickering
Non-Executive Director
Patrick Noel Butler
Non-Executive Director

Stock Details

EPIC
HIK
ISIN
GB00B0LCW083
Shares in Issue
240,678,894
Market cap
£2,286.45m

Analyst Views (7)

Strong Buy
 
14.29%
Buy
 
0.00%
Hold
 
57.14%
Sell
 
28.57%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
892.20p
Bid Price
891.80p
Ask Price
892.20p
Volume
486363
Change Today
-5.80p
% Change Today
-0.65%
Open
899.60p
Previous Close
892.20p
Intraday High
903.80p
Intraday Low
873.20p
52 Week High
2346.00p
52 Week Low
840.60p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Hikma Pharmaceuticals Intra-day Chart

Hikma Pharmaceuticals News

News in this section is provided by MoneyAM

Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 15 Feb 2018 | 08:10 Hikma appoints chief scientific officer and head of R&D 15 Jan 2018 | 09:39 Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC 10 Jan 2018 | 12:20 Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC 04 Dec 2017 | 10:10 Hikma Ventures investment in Prognos 01 Dec 2017 | 07:38 Hikma invests in Biolinq 27 Nov 2017 | 13:49 Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 14 Nov 2017 | 11:20 Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC 10 Nov 2017 | 09:30 Broker Forecast - HSBC issues a broker note on Hikma Pharmaceuticals PLC 10 Nov 2017 | 08:10 Broker Forecast - Numis issues a broker note on Hikma Pharmaceuticals PLC 09 Nov 2017 | 12:40 Broker Forecast - Stifel issues a broker note on Hikma Pharmaceuticals PLC 09 Nov 2017 | 12:30 UK housing market setback weighs on FTSE 09 Nov 2017 | 12:04 Hikma maintains revenues forecasts 09 Nov 2017 | 08:13 Hikma US unit launches generic equivalents to Ancobon 03 Nov 2017 | 09:14 Hikma US unit launches Pantoprazole sodium for injection 30 Oct 2017 | 09:43 Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC 06 Oct 2017 | 09:10 Broker Forecast - Cantor Fitzgerald issues a broker note on Hikma Pharmaceuticals PLC 01 Sep 2017 | 11:00 Broker Forecast - Stifel issues a broker note on Hikma Pharmaceuticals PLC 29 Aug 2017 | 11:40 Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC 25 Aug 2017 | 08:00 Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC 24 Aug 2017 | 08:20 Broker Forecast - Goldman Sachs issues a broker note on Hikma Pharmaceuticals PLC 22 Aug 2017 | 09:20 Peel Hunt cuts earnings by 30% for Hikma 21 Aug 2017 | 10:27 Broker Forecast - Morgan Stanley issues a broker note on Hikma Pharmaceuticals PLC 21 Aug 2017 | 10:20 Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC 21 Aug 2017 | 08:50 Broker Forecast - Peel Hunt issues a broker note on Hikma Pharmaceuticals PLC 21 Aug 2017 | 08:00 FTSE remains weak on underwhelming financial stocks 17 Aug 2017 | 16:49 Slump in banking stocks hit FTSE 17 Aug 2017 | 11:57 FTSE weaker as pound strengthens 17 Aug 2017 | 08:49 Hikma core operating profits up 17 Aug 2017 | 07:34 FLASH: Hikma core operating profits up 17 Aug 2017 | 07:09

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Tangible Assets
969.0
507.0
Intangible Assets & Goodwill
1,719.0
607.0
Investments & Other Non-Current Assets
227.0
123.0
Total Non-Current Assets
2,915.0
1,237.0
Inventory
459.0
251.0
Trade & Receivables
759.0
488.0
Cash & Receivables
155.0
553.0
Other Current Assets & Assets Held for Resale
75.0
68.0
Total Assets
4,363.0
2,597.0

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Short Term Liabilities
918.0
592.0
Long Term Liabilities
1,034.0
653.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
1,952.0
1,245.0

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Net Assets
2,411.0
1,352.0

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Share Capital
40.0
35.0
Minority Interests
15.0
15.0
Retained Earnings
0.0
0.0
Share Premium Account
282.0
282.0
Other Equity
2,074.0
1,020.0
Total Equity
2,411.0
1,352.0

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Cashflow from Operating Activities
293.0
366.0
Cashflow Before Financing
-402.0
204.0
Increase / Decrease in Cash
-383.0
281.0

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2016
31 Dec 2015
Turnover
1,950.0
1,440.0
Cost of Sales
964.0
622.0
Gross Profit
986.0
818.0
Operating Profit
302.0
381.0
Pre-Tax Profit
210.0
318.0
Profit / Loss for the Year
155.0
254.0

Dividend History

Data has been provided by MoneyAM

Period
Ex-Dividend Date
Payment Date
H1 Dividend
24 Aug 2017
22 Sep 2017
H2 Dividend
06 Apr 2017
25 May 2017
H1 Dividend
01 Sep 2016
30 Sep 2016
H2 Dividend
07 Apr 2016
19 May 2016
H1 Dividend
27 Aug 2015
25 Sep 2015
H2 Dividend
16 Apr 2015
21 May 2015
Special Dividend
27 Aug 2014
26 Sep 2014
H1 Dividend
27 Aug 2014
26 Oct 2014
Special Dividend
23 Apr 2014
22 May 2014
H2 Dividend
23 Apr 2014
22 May 2014
Special Dividend
04 Sep 2013
07 Oct 2013
H1 Dividend
04 Sep 2013
07 Oct 2013
H2 Dividend
17 Apr 2013
23 May 2013
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.